Benzinga | Jul 27, 2020 08:18AM EDT

SVB Leerink Maintains Outperform on Blueprint Medicines, Raises Price Target to $107

SVB Leerink maintains Blueprint Medicines (NASDAQ:BPMC) with a Outperform and raises the price target from $106 to $107.